CLAIMS

1. The use of the compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one or of non-toxic salts or isomers thereof for the preparation of a medicament for the treatment of tumors involving a tyrosine kinase selected from Met, PDGF-R, FGF-R1, FGF-R3, Kit, or an oncoprotein of the Ret family.

2. The use according to claim 1, for the treatment of tumors expressing RET oncoproteins carrying activating sequence mutations.

3. The use according to claim 2, wherein the RET oncoproteins include MEN2 associated mutations.

4. The use according to claim 3, wherein the activated sequence mutations are RET/MEN2A (C634R), RET/MEN2A (C634W) and RET/MEN2B (M918T).

5. The use according to claim 2-4, for the treatment of medullary thyroid carcinomas, pheochromocytoma, parathyroid hyperplasia, enteric ganglioneuroma.

6. The use according to claim 1, for the treatment of tumors bearing a Met-activating alteration.

7. The use according to claim 6, wherein said tumors are of epithelial origin.

8. The use according to claim 7, for the treatment of kidney tumor.

9. The use according to claim 1, for the treatment of tumors expressing constitutively-activated Kit.

10. The use according to claim 9, wherein Kit is constitutively activated following to sequence mutations or involvement in autocrine loops.

11. The use according to claim 9, for the treatment of gastrointestinal stromal tumors, small cell lung carcinomas, leukemias or seminomas.

12. The use according to claim 1, for the treatment of tumors involving the uncontrolled activation of PDGF-R.

13. The use according to claim 12, wherein said tumors are gliomas and dermatofibrosarcoma protuberans.

14. The use according to claim 1, for the treatment of tumors highly expressing FGF-R1 and/or its ligand bFGF.

15. The use according to claim 14, wherein said tumors are melanomas and gliomas.

16. The use according to claim 1, for the treatment of tumors expressing constitutive activating forms of FGF-R3.

17. The use according to claim 16, wherein said tumors are multiple myeloma, bladder and cervix carcinomas.

18. The use according to claims 12 and 14, for the inhibition of tumor angiogenesis.

19. A pharmaceutical composition containing as active ingredient the compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient or diluent.

20. The pharmaceutical composition according to claim 19, wherein said pharmaceutically acceptable carrier or diluent is suitable for oral or parenteral administration.

21. The pharmaceutical composition according to claim 19, further comprising a anti-tumor or anti-cancer agent which is different from 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one.

22. The pharmaceutical composition according to claim 19, wherein said anti-tumor or anti-cancer agent is selected from the group consisting of adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside, cyclophosphamide, 5-FU, hexamethylmelamine, carboplatin,

cisplatin, idarubycin, paclitaxel, docitaxel, topotecan, irinotecam, gencitabine, Lpam, BCNU and VP-16.

23. A kit comprising, in separate containers, a compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one or a pharmaceutically acceptable salt thereof and an anti-cancer or anti-tumor agent.

24. The kit according to claim 23, wherein said anti-tumor or anti-cancer agent is selected from the group consisting of adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside, cyclophosphamide, 5-FU, hexamethylmelamine, carboplatin, cisplatin, idarubycin, paclitaxel, docetaxel, topotecan, irinotecam, gemcitabine, L-PAM, BCNU and VP-16.